INCIDENCE OF ACUTE PANCREATITIS FROM GLP-1 RECEPTOR AGONISTS USAGE
DOI:
https://doi.org/10.47820/recima21.v5i9.5669Keywords:
pancreatitis; incretins; glucagon-like peptide-1.Abstract
Incretins are appetite-regulating hormones secreted by the intestine in response to food intake. Glucagon-like peptide (GLP-1) is an example, with the action of increasing insulin release and decreasing glucagon release. GLP-1 mimetics, such as Liraglutide or Semaglutide, have been used to treat type 2 diabetes mellitus and, recently, to treat obesity. However, there is concern about their use due to the risk of worrying side effects, such as acute pancreatitis. Objectives: to evaluate the incidence of acute pancreatitis cases due to the use of GLP-1 analogue drugs. Materials and methods: This is an integrative review, in which the guiding question was “Can GLP-1 analogues lead to the development of acute pancreatitis?”. The search for articles was carried out in the PubMed database using the terms “Glucagon-like peptide”, “pancreatitis” and “GLP-1 analogs”, combined with each other by the Boolean operator AND. Results and discussion: The results demonstrated that GLP-1 analogs have a low potential to lead to the development of acute pancreatitis. Among the articles that found this correlation, some factors, such as certain previous pathologies of the patients, may have been a confounding factor, considering that these patients would already have a predisposition to develop acute pancreatitis. Conclusion: It is suggested that some agonists have a very low risk of developing pancreatitis, and individual risk factors for pancreatitis should be taken into account when prescribing such medication.
Downloads
References
ALVES, Carlos; BATEL-MARQUES, Francisco; MACEDO, Ana F. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes research and clinical practice, v. 98, n. 2, p. 271-284, 2012. DOI: https://doi.org/10.1016/j.diabres.2012.09.008
DE SOUSA, Luís Manuel Mota et al. A metodologia de revisão integrativa da literatura em enfermagem. Revista investigação em enfermagem, v. 21, n. 2, p. 17-26, 2017.
ELASHOFF, Michael et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, v. 141, n. 1, p. 150-156, 2011. DOI: https://doi.org/10.1053/j.gastro.2011.02.018
ERCOLE, Flávia Falci; MELO, Laís Samara de; ALCOFORADO, Carla Lúcia Goulart Constant. Revisão integrativa versus revisão sistemática. Reme: Revista Mineira de Enfermagem, v. 18, n. 1, p. 09-11, 2014. DOI: https://doi.org/10.5935/1415-2762.20140001
FILIPPATOS, Theodosios; PANAGIOTOPOULOU, Thalia & ELISAF, Moses. Adverse Effects of GLP-1 Receptor Agonists. Rev. diabetic studies, v. 11, v. 3-4, p. 202-230, 2014. DOI: https://doi.org/10.1900/RDS.2014.11.202
HOLST, Juul Jens, GASBJERG, Laerk. Smidt, & ROSENKILDE, Mette Marie. The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology, v. 162, n. 7, 2021. DOI: https://doi.org/10.1210/endocr/bqab065
KRISTENSEN, Soren et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol, v. 7, n. 10, p. 776-785, 2019. DOI: https://doi.org/10.1016/S2213-8587(19)30249-9
LIU, L. et al. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol, v. 13, p. 1-10, 2022. DOI: https://doi.org/10.3389/fendo.2022.1043789
MENDES, Karina Dal Sasso; SILVEIRA, Renata Cristina de Campos Pereira; GALVÃO, Cristina Maria. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, v. 17, p. 758-764, 2008. DOI: https://doi.org/10.1590/S0104-07072008000400018
NAUCK Michael A.; FRIEDRICH, Nele. Do GLP-1-based therapies increase cancer risk? Diabetes Care, v. 36, p. 245-52, 2013. DOI: https://doi.org/10.2337/dcS13-2004
NAUCK, Michael. A. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular metabolism, v. 46, p. 101-102, 2021. DOI: https://doi.org/10.1016/j.molmet.2020.101102
PATOULIAS, Dimitrius et al. Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care. Pragmatic and observational research, v. 15, p. 139-149, 2024. DOI: https://doi.org/10.2147/POR.S471476
PEDROSA, Maurício Reis et al. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Current atherosclerosis reports, v. 24, n. 11, p. 867-884, 2022. DOI: https://doi.org/10.1007/s11883-022-01062-2
SINGH, Sonal et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med, v. 173, n. 7, p. 534-9, 2013. DOI: https://doi.org/10.1001/jamainternmed.2013.2720
SIVARAMAN, S. C.; BARBER, T. M.; O’HARE, P.; RANDEVA, H. S. Glucagon-like peptide-1 based therapies: Effects beyond blood glucose control. The British Journal of Diabetes & Vascular Disease, v. 13, n. 5-6, p. 229-237, 2013. DOI: https://doi.org/10.1177/1474651413504119
STEINBERG, William M. et al. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes care, v. 40, n. 7, p. 839-848, 2017. DOI: https://doi.org/10.2337/dc16-2684
VETTER, Marion L et al. Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. Diabetes Ther, v. 10, n. 4, p. 1249-1270, 2019. DOI: https://doi.org/10.1007/s13300-019-0627-1
ZHAO, Xin et al. “GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.” Frontiers in endocrinology, v. 12, p. 1-19, 2021. DOI: https://doi.org/10.3389/fendo.2021.721135
Downloads
Published
How to Cite
License
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
Clique para ver detalhes 
